C-C chemokine receptor 2 and C-C chemokine receptor 5 genotypes in patients treated for chronic hepatitis C virus infection

Immunologic Research

Volumn 26, Issue 1-3, 2002, Pages 167-175

  Dorak, M T ^a   Folayan, G O ^a   Niwas, S ^a   Van Leeuwen, D J ^b   Yee, L J ^a   Tang, J ^a   Kaslow, R A ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b University of Alabama at Birmingham   (United States)

Author keywords

C C chemokine receptor 5; Genotype; Haplotype; Hepatitis C virus; Human immunodeficiency virus; Interferon ribavirin; Viral load

Indexed keywords

ALPHA2B INTERFERON; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR5; RIBAVIRIN;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENOTYPE; HAPLOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HOMOZYGOSITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; VIREMIA; VIRUS LOAD; VIRUS REPLICATION;

ADULT; AGED; ANTIVIRAL AGENTS; FEMALE; GENOTYPE; HAPLOTYPES; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; PROMOTER REGIONS (GENETICS); RECEPTORS, CCR5; RECEPTORS, CHEMOKINE; RIBAVIRIN; RNA, VIRAL; VARIATION (GENETICS); VIREMIA;

EID: 0036394290     PISSN: 0257277X     EISSN: None     Source Type: Journal    
DOI: 10.1385/IR:26:1-3:167     Document Type: Article

References (37)

1. McNicholl JM, Downer MV, Udhayakumar V, Alper CA, Swerdlow DL: Host-pathogen interactions in emerging and reemerging infectious diseases: a genomic perspective of tuberculosis, malaria, human immunodeficiency virus infection, hepatitis B, and cholera. Annu Rev Public Health 2000;21:15-46.
2. Cooke GS, Hill AV: Genetics of susceptibility to human infectious disease. Nat Rev Genet 2001;2:967-977.
3. Kaslow RA, McNicholl JM: Genetic determinants of HIV-1 infection and its manifestations. Proc Assoc Am Physicians 1999;111:299-307.
4. Carrington M, Nelson GW, Martin MP, et al: HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage. Science 1999;283:1748-1752.
5. Tang J, Shelton B, Makhatadze NJ, et al: Distribution of chemokine receptor CCR2 and CCR5 genotypes and their relative contribution to human immunodeficiency virus type 1 (HIV-1) seroconversion, early HIV-1 RNA concentration in plasma, and later disease progression. J Virol 2002;76:662-672.
6. Thursz MR: Host genetic factors influencing the outcome of hepatitis. J Viral Hepat 1997;4:215-220.
7. Powell EE, Edwards-Smith CJ, Hay JL, et al: Host genetic factors influence disease progression in chronic hepatitis C. Hepatology 2000;31:828-833.
8. Thio CL, Thomas DL, Carrington M: Chronic viral hepatitis and the human genome. Hepatology 2000;31:819-827.
9. Thursz M. Genetic susceptibility in chronic viral hepatitis. Antiviral Res 2001;52:113-116.
10. Thomas DL, Astemborski J, Rai RM, et al: The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 2000;284:450-456.
11. Lauer GM, Walker BD: Hepatitis C virus infection. N Engl J Med 2001;345:41-52.
12. Villano SA, Vlahov D, Nelson KE, Cohn S, Thomas DL: Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology 1999;29:908-914.
13. Edwards-Smith CJ, Jonsson JR, Purdie DM, Bansal A, Shorthouse C, Powell EE: Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis C to interferon alfa. Hepatology 1999;30:526-530.
14. Knolle PA, Kremp S, Hohler T, Krummenauer F, Schirmacher P, Gerken G: Viral and host factors in the prediction of response to interferon-alpha therapy in chronic hepatitis C after long-term follow-up. J Viral Hepat 1998;5:399-406.
15. Thio CL, Carrington M, Marti D, et al: Class II HLA alleles and hepatitis B virus persistence in African Americans. J Infect Dis 1999;179:1004-1006.
16. Thursz M, Yallop R, Goldin R, Trepo C, Thomas HC: Influence of MHC class II genotype on outcome of infection with hepatitis C virus. The HENCORE group. Hepatitis C European Network for Cooperative Research. Lancet 1999;354:2119-2124.
17. Harcourt G, Hellier S, Bunce M, et al: Effect of HLA class II genotype on T helper lymphocyte responses and viral control in hepatitis C virus infection. J Viral Hepat 2001;8:174-179.
18. Yee LJ, Tang J, Herrera J, Kaslow RA, van Leeuwen DJ: Tumor necrosis factor gene polymorphisms in patients with cirrhosis from chronic hepatitis C virus infection. Genes Immun 2000;1:386-390.
19. Yee LJ, Tang J, Gibson AW, Kimberly R, Van Leeuwen DJ, Kaslow RA: Interleukin 10 polymorphisms as predictors of sustained response in antiviral therapy for chronic hepatitis C infection. Hepatology 2001;33:708-712.
20. Woitas RP, Ahlenstiel G, Brackmann HH, Matz B, Rockstroh JK, Spengler U: CCR5-D32 mutation - protective against HIV, but bad for hepatitis C virus? 8th Conference on Retroviruses and Opportunistic Infections, 2000:192-193, #19 (abstract no. 499).
21. Woitas RP, Ahlenstiel G, Rockstroh JK, et al: Increased frequency of the CC-chemokine receptor 5-D32/D32 genotype in hepatitis C. J Hepatol 2001;34(Suppl. 1):164 [abstract no. 1071).
22. Woitas RP, Ahlenstiel G, Iwan A, et al: Frequency analysis of the HIV-protective CC chemokine receptor 2B V64I mutation in patients with Hepatitis C and HIV/HCV coinfection. Hepatology 2001;34:480A (abstract no. 1231).
23. Yoshie O, Imai T, Nomiyama H: Chemokines in immunity. Adv Immunol 2001;78:57-110.
24. Tang J, Rivers C, Karita E, et al: Allelic variants of human beta-chemokine receptor 5 (CCR5) promoter: evolutionary relationships and predictable association with HIV-1 disease progression. Genes Immun 1999;1:20-27.
25. McHutchison JG, Gordon SC, Schiff ER, et al: Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998;339:1485-1492.
26. Poynard T, Marcellin P, Lee SS, et al: Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998;352:1426-1432.
27. Yee LJ, Weiss HL, Langner RG, Herrera J, Kaslow RA, van Leeuwen DJ: Risk factors for acquisition of hepatitis C virus infection: a case series and potential implications for disease surveillance. BMC Infect Dis 2001;1:8.
28. Gonzalez E, Bamshad M, Sato N, et al: Race-specific HIV-1 disease modifying effects associated with CCR5 haplotypes. Proc Natl Acad Sci USA 1999;96:12,004-12,009.
29. Mangano A, Gonzalez E, Dhanda R, et al: Concordance between the CC chemokine receptor 5 genetic determinants that alter risks of transmission and disease progression in children exposed perinatally to human immunodeficiency virus. J Infect Dis 2001;183:1574-1585.
30. Howard OM, Shirakawa AK, Turpin JA, et al: Naturally occurring CCR5 extracellular and transmembrane domain variants affect HIV-1 co-receptor and ligand binding function. J Biol Chem 1999;274:16,228-16,234.
31. Alric L, Izopet J, Fort M, et al: Study of the association between major histocompatibility complex class II genes and the response to interferon alpha in patients with chronic hepatitis C infection. Hum Immunol 1999;60:516-523.
32. Neumann AU, Lam NP, Dahari H, et al: Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus. J Infect Dis 2000;182:28-35.
33. Zein NN: Clinical significance of hepatitis C virus genotypes. Clin Microbiol Rev 2000;13:223-235.
34. Alric L, Fort M, Izopet J, et al: Study of host- and virus-related factors associated with spontaneous hepatitis C virus clearance. Tissue Antigens 2000;56:154-158.
35. Dean M, Carrington M, Winkler C, et al: Genetic restriction of HIV-1 infection and progression to AIDS by a common deletion allele of the chemokine receptor 5 structural gene. Science 1996;273:1856-1862.
36. Lu Y, Nerurkar VR, Dashwood WM, et al: Genotype and allele frequency of a 32-base pair deletion mutation in the CCR5 gene in various ethnic groups: absence of mutation among Asians and Pacific Islanders. Int J Infect Dis 1999;3:186-191.
37. Libert F, Cochaux P, Beckman G, et al: The deltaccr5 mutation conferring protection against HIV-1 in Caucasian populations has a single and recent origin in Northeastern Europe. Hum Mol Genet 1998;7:399-406.